These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36929778)

  • 1. Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Huang SC; Kao JH
    Hepatology; 2023 Jul; 78(1):E11. PubMed ID: 36929778
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: hepatic steatosis and fibrosis in chronic hepatitis B-the chicken-and-egg conundrum.
    Huang SC; Kao JH
    Aliment Pharmacol Ther; 2022 Jan; 55(1):143-144. PubMed ID: 34907555
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: hepatic steatosis and fibrosis in chronic hepatitis B-the chicken-and-egg conundrum. Authors' reply.
    Zheng Q; Nguyen MH
    Aliment Pharmacol Ther; 2022 Jan; 55(1):145-146. PubMed ID: 34907551
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: hepatic steatosis in chronic hepatitis B-viral, metabolic or treatment-related?
    Morozov S; Batskikh S
    Aliment Pharmacol Ther; 2022 Jan; 55(1):147-148. PubMed ID: 34907566
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: hepatic steatosis in chronic hepatitis B-viral, metabolic or treatment-related? Authors' reply.
    Zheng Q; Nguyen MH
    Aliment Pharmacol Ther; 2022 Jan; 55(1):149. PubMed ID: 34907560
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Mak LY; Yuen MF; Seto WK
    Hepatology; 2023 Jul; 78(1):E12-E13. PubMed ID: 36929950
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B.
    Leow YW; Chan WK
    J Viral Hepat; 2023 Aug; 30(8):712. PubMed ID: 37337691
    [No Abstract]   [Full Text] [Related]  

  • 8. Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate.
    Pokora-Rodak A; Krzowska-Firych J; Tomasiewicz K
    Ann Agric Environ Med; 2021 Sep; 28(3):458-462. PubMed ID: 34558270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?
    Atalay R; Sayar S; Ayrancı FG; Çakmak Ş; Tanboğa İH; Doğanay L; Özdil K
    Turk J Gastroenterol; 2022 Jul; 33(7):587-595. PubMed ID: 35879916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatic steatosis in chronic hepatitis B: prevalence, risk factors, and impact on fibrosis and therapeutic response].
    Ben Slama Trabelsi A; Ksiaa M; Souguir A; Issaoui D; Sriha B; Ajmi S
    Tunis Med; 2013 Jul; 91(7):431-4. PubMed ID: 24008872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B.
    Jin X; Chen YP; Yang YD; Li YM; Zheng L; Xu CQ
    PLoS One; 2012; 7(3):e34198. PubMed ID: 22479562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B].
    Shi JP; Lu L; Qian JC; Ang J; Xun YH; Guo JC; Shi WL; Wang YF; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):285-8. PubMed ID: 22964150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients.
    Chen XL; Han YD; Wang H
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5640-5646. PubMed ID: 30229840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection.
    Cindoruk M; Karakan T; Unal S
    J Clin Gastroenterol; 2007; 41(5):513-7. PubMed ID: 17450036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B.
    Mao X; Mak LY; Seto WK
    Clin Mol Hepatol; 2023 Jul; 29(3):690-692. PubMed ID: 37254487
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B.
    Gong L; Liu J; Wang J; Lou GQ; Shi JP
    Transplant Proc; 2015 Dec; 47(10):2886-91. PubMed ID: 26707308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.
    Lesmana LA; Lesmana CR; Pakasi LS; Krisnuhoni E
    Acta Med Indones; 2012 Jan; 44(1):35-9. PubMed ID: 22451183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis.
    Gordon A; McLean CA; Pedersen JS; Bailey MJ; Roberts SK
    J Hepatol; 2005 Jul; 43(1):38-44. PubMed ID: 15876468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of clinical and pathological features of chronic hepatitis B with hepatic steatosis].
    Mi YQ; Liu YG; Xu L; Fan JG; Zhang H; Ping L; Shi RF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):817-20. PubMed ID: 19958639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis.
    Thomopoulos KC; Arvaniti V; Tsamantas AC; Dimitropoulou D; Gogos CA; Siagris D; Theocharis GJ; Labropoulou-Karatza C
    Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):233-7. PubMed ID: 16462535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.